Please login to the form below

Not currently logged in
Email:
Password:

Forest looks to extend Alzheimer's drug

Forest Laboratories has announced that patients taking a once-daily formulation of its Alzheimer's drug Namenda (memantine) in a late-stage clinical trial had a significant improvement in symptoms compared with those who received a placebo.

Forest Laboratories has announced that patients taking a once-daily formulation of its Alzheimer's drug Namenda (memantine) in a late-stage clinical trial had a significant improvement in symptoms compared with those who received a placebo.

Analysts believe this is an attempt by the pharma company to extend the patent of the drug, which is already sold in a twice-daily 10mg formulation.

Forest has evaluated the efficacy and safety of an once-daily 28mg extended release version of Namenda in patients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor. 

"The higher dosage and once-daily formulation will provide patients with the efficacy and tolerability expected from Namenda, in a more convenient once-daily form," said Ivan Gergel, senior vice president of scientific affairs at Forest Laboratories and President of the Forest Research Institute.

Based on the results of this study, Forest plans to pursue a new drug application for the Namenda extended-release once-daily formulation.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics